Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Larimar Therapeutics, Inc. Director's Dealing 2017

Oct 11, 2017

33359_dirs_2017-10-11_a1341375-9951-4cc5-9d1b-1160c12b3d00.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2017-10-09

Reporting Person: Hatfield Jeffrey S. (Director, Chief Executive Officer)